Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Joy M. Cote
Observed names:
Joy Cote,
Joy M Cote,
Joy Marie Cote
Institution:
Prelude Therapeutics Incorporated (United States)
Observed institutions:
Wesleyan University,
Fox Chase Cancer Center,
Prelude Therapeutics Incorporated (United States),
College of Mount Saint Vincent
ORCID:
0000-0002-2570-267X
Observed ORCID:
0000-0002-2570-267X
OpenAlex ID:
A5084127002
T cell activation triggers reversible inosine-5′-monophosphate dehydrogenase assembly
2018
·
Krisna C. Duong-Ly
, Yin-Ming Kuo
, et al.
·
Journal of Cell Science
·
51
PDF
The Glycosyltransferases of LPS Core: A Review of Four Heptosyltransferase Enzymes in Context
2017
·
Joy Cote
, Erika Taylor
·
International Journal of Molecular Sciences
·
50
PDF
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
2025
·
Michael Hulse
, Min Wang
, et al.
·
Cancer Research
·
31
Two factor authentication: Asf1 mediates crosstalk between H3 K14 and K56 acetylation
2019
·
Joy M Cote
, Yin-Ming Kuo
, et al.
·
Nucleic Acids Research
·
27
The Stories Tryptophans Tell: Exploring Protein Dynamics of Heptosyltransferase I from Escherichia coli
2017
·
Joy M. Cote
, Carlos A. Ramirez-Mondragon
, et al.
·
Biochemistry
·
17
Discovery of first-in-class nanomolar inhibitors of heptosyltransferase I reveals a new aminoglycoside target and potential alternative mechanism of action
2022
·
Jozafina Milicaj
, Bakar A. Hassan
, et al.
·
Scientific Reports
·
13
PDF
Exploring allosteric activation of LigAB from Sphingobium sp. strain SYK-6 through kinetics, mutagenesis and computational studies
2015
·
Kevin Patrick Barry
, Abraham Ngu
, et al.
·
Archives of Biochemistry and Biophysics
·
11
mulet (mlt) encodes a tubulin-binding cofactor E-like homolog required for spermatid individualization in Drosophila melanogaster
2012
·
James J. Fabrizio
, Nour Aqeel
, et al.
·
Fly
·
9
PDF
Opposites Attract: Escherichia coli Heptosyltransferase I Conformational Changes Induced by Interactions between the Substrate and Positively Charged Residues
2020
·
Joy M. Cote
, Cody J. S. Hecht
, et al.
·
Biochemistry
·
8
Identification of triazolyl KAT6 inhibitors via a templated fragment approach
2024
·
Chun Chen
, Sarah B. Pawley
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
7
Synthesis, kinetics and inhibition of Escherichia coli Heptosyltransferase I by monosaccharide analogues of Lipid A
2018
·
Noreen K. Nkosana
, Daniel J. Czyzyk
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
6
Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2
2024
·
Artem Shvartsbart
, Koichi Ito
, et al.
·
Cancer Research
·
4
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
2023
·
Koichi Ito
, Michael Hulse
, et al.
·
Molecular Cancer Therapeutics
·
4
Abstract 5793: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile
2026
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789
2025
·
Min Wang
, Miles Cowart
, et al.
·
Cancer Research
·
2
Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
2025
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Figure S10 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S11 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Show more works
View as search
Works count:
39
Citation count:
244
H-index:
8
I10-index:
7
Year
Topic
Type